coomassie brilliant blue has been researched along with Cognition Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, L; Chen, X; Hu, J; Jiang, L; Wang, C; Wang, Q; Wei, X; Xu, S; Zhang, J; Zheng, B | 1 |
| Deshmukh, R; Koushal, P; Kumar, P; Reddy, BV; Soni, N | 1 |
2 other study(ies) available for coomassie brilliant blue and Cognition Disorders
| Article | Year |
|---|---|
Brilliant Blue G improves cognition in an animal model of Alzheimer's disease and inhibits amyloid-β-induced loss of filopodia and dendrite spines in hippocampal neurons.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Cells, Cultured; Cognition; Cognition Disorders; Dendritic Spines; Disease Models, Animal; Hippocampus; Mice, Inbred ICR; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Pseudopodia; Rats, Sprague-Dawley; Rosaniline Dyes; Spatial Memory | 2014 |
Effect of GLT-1 modulator and P2X7 antagonists alone and in combination in the kindling model of epilepsy in rats.
Topics: Animals; Brain; Ceftriaxone; Cognition Disorders; Convulsants; Dose-Response Relationship, Drug; Epilepsy; Excitatory Amino Acid Transporter 2; Kindling, Neurologic; Lipid Peroxidation; Male; Oxidative Stress; Pentylenetetrazole; Purinergic P2X Receptor Antagonists; Rats; Rosaniline Dyes; Seizures | 2015 |